Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.20 USD

201.20
7,194,067

-0.48 (-0.24%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study

Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar

JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott

Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT).

I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal

I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.

Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA

Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down

Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.

Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance

Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag

AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.

AbbVie (ABBV) Q2 Earnings Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.81% and 0.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 16.57% and 5.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Derek Lewis headshot

AbbVie Q2 Preview: Can Shares Retain Their Strength?

There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.

AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.

Zacks Investment Ideas feature highlights: Coca-Cola, Emerson Electric and AbbVie

Coca-Cola, Emerson Electric and AbbVie have been highlighted in this Investment Ideas article.

Derek Lewis headshot

3 Dividend Kings Suited Perfectly for Income Investors

Meeting the parameters to join the elite Dividend King group speaks volumes about these companies' well-established and thriving nature.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie

Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.